argenx SE – (NASDAQ:ARGX) – Piper Jaffray Companies lifted their FY2018 earnings estimates for argenx in a research report issued to clients and investors on Monday, December 3rd. Piper Jaffray Companies analyst E. Tenthoff now expects that the company will earn ($1.89) per share for the year, up from their previous forecast of ($1.91). Piper Jaffray Companies has a “Overweight” rating and a $161.00 price target on the stock. Piper Jaffray Companies also issued estimates for argenx’s Q4 2018 earnings at ($0.61) EPS, Q1 2019 earnings at ($0.59) EPS, Q2 2019 earnings at ($0.63) EPS, Q3 2019 earnings at ($0.64) EPS, Q4 2019 earnings at ($0.71) EPS and FY2019 earnings at ($2.57) EPS.

ARGX has been the topic of a number of other reports. Zacks Investment Research raised argenx from a “hold” rating to a “buy” rating and set a $104.00 target price on the stock in a research note on Tuesday, November 13th. Wedbush reaffirmed an “outperform” rating and set a $125.00 price objective (down from $130.00) on shares of argenx in a research report on Monday, November 5th. Stifel Nicolaus reaffirmed a “buy” rating on shares of argenx in a research report on Thursday, November 1st. SunTrust Banks increased their price objective on argenx to $132.00 and gave the company an “in-line” rating in a research report on Tuesday, September 18th. Finally, JMP Securities increased their price objective on argenx to $150.00 and gave the company an “outperform” rating in a research report on Monday, September 17th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. argenx presently has an average rating of “Buy” and a consensus price target of $136.00.

NASDAQ ARGX opened at $103.60 on Thursday. argenx has a 12 month low of $29.33 and a 12 month high of $111.43. The firm has a market capitalization of $3.40 billion, a PE ratio of -73.86 and a beta of 1.67.

Several institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp boosted its position in shares of argenx by 11.5% during the second quarter. Northern Trust Corp now owns 12,418 shares of the company’s stock valued at $1,029,000 after buying an additional 1,285 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of argenx by 22.1% during the second quarter. Dimensional Fund Advisors LP now owns 7,559 shares of the company’s stock valued at $626,000 after buying an additional 1,366 shares during the last quarter. Capital Fund Management S.A. purchased a new stake in shares of argenx during the third quarter valued at $212,000. Stevens Capital Management LP purchased a new stake in shares of argenx during the third quarter valued at $214,000. Finally, TD Asset Management Inc. boosted its position in shares of argenx by 8.2% during the second quarter. TD Asset Management Inc. now owns 38,832 shares of the company’s stock valued at $3,218,000 after buying an additional 2,952 shares during the last quarter. 64.40% of the stock is currently owned by institutional investors.

argenx Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Read More: Cost of Debt

Earnings History and Estimates for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.